Dexmedetomidine enhances hypoxia‑induced cancer cell progression

Chen,Hua   Yan; Li,Geng   Hua; Tan,Guo   Cheng; Liang,Hua; Lai,Xiao  Hong; Huang,Qiong; Zhong,Ji  Ying

doi:10.3892/etm.2019.8136

Dexmedetomidine enhances hypoxia‑induced cancer cell progression

Authors:
- Hua Yan Chen
- Geng Hua Li
- Guo Cheng Tan
- Hua Liang
- Xiao Hong Lai
- Qiong Huang
- Ji Ying Zhong
View Affiliations

Affiliations: Department of Anesthesiology, Affiliated FoShan Hospital of Sun Yat‑Sen University, Foshan, Guangdong 528000, P.R. China, Department of Anesthesiology, Affiliated Luoding Hospital of Guangdong Medical University, Luoding, Guangdong 527200, P.R. China, Department of Medical Statistics, Affiliated Chancheng Central Hospital of Guangdong Medical University, Foshan, Guangdong 528000, P.R. China
Published online on: October 25, 2019 https://doi.org/10.3892/etm.2019.8136
Pages: 4820-4828
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dexmedetomidine (DEX) is widely used in perioperative settings for analgesia and sedation; however, little is known about its effects on the hypoxia‑induced progression of tumor cells. In the present study, the effects of DEX on hypoxia‑induced growth and metastasis of lung cancer cells and colorectal cancer cells was examined. A549 cells and HCT116 cells were treated with normoxia, hypoxia, co‑treatment of hypoxia and DEX, and atipamezole (an α2 adrenoceptor antagonist) for 4 h. The proliferation rate of cells was determined by MTT assays. Cell metastatic potential was evaluated by Transwell assays. Survivin and hypoxia inducible factor (HIF)‑1α were detected by western blotting. Matrix metalloproteinase (MMP)‑2 and MMP‑9 were measured using reverse transcription‑quantitative PCR. It was demonstrated that hypoxia treatment promoted the proliferation and may promote the metastasis of the two cancer cell lines. DEX substantially contributed to the survival and aggressiveness of the two cancer cell lines following hypoxia. Furthermore, DEX upregulated the expression of survivin, MMP‑2, MMP‑9 and HIF‑1α in the two cancer cell lines in response to hypoxia. Finally, the effects of DEX on the hypoxia‑induced growth and metastatic potential of cancer cells were reversed by atipamezole. Collectively, DEX enhances the hypoxia‑induced progression of lung cancer cells and colorectal cancer cells by regulating HIF‑1α signaling, which may be associated with the α2 adrenoceptor pathway.

View Figures

View References

1	Hopewood P and Milroy MJ and Milroy MJ: Cancer Statistics: Global and NationalQuality Cancer Care. Springer; New York, NY, USA: pp. 29–35. 2018
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Hiller JG, Perry NJ, Poulogiannis G, Riedel B and Sloan EK: Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 15:205–218. 2018. View Article : Google Scholar : PubMed/NCBI
4	Olcina MM, Kim RK, Melemenidis S, Graves EE and Giaccia AJ: The tumour microenvironment links complement system dysregulation and hypoxic signalling. Br J Radiol. 15:201800692018.(Epub ahead of print). View Article : Google Scholar
5	Wigerup C, Påhlman S and Bexell D: Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 164:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gupta K, Prasad A, Nagappa M, Wong J, Abrahamyan L and Chung FF: Risk factors for opioid-induced respiratory depression and failure to rescue: A review. Curr Opin Anaesthesiol. 31:110–119. 2018. View Article : Google Scholar : PubMed/NCBI
7	Campos JH and Feider A: Hypoxia during one-lung ventilation-a review and update. J Cardiothorac Vasc Anesth. 32:2330–2338. 2018. View Article : Google Scholar : PubMed/NCBI
8	Soltanizadeh S, Degett TH and Gogenur I: Outcomes of cancer surgery after inhalational and intravenous anesthesia: A systematic review. J Clin Anesth. 42:19–25. 2017. View Article : Google Scholar : PubMed/NCBI
9	Cassinello F, Prieto I, del Olmo M, Rivas S and Strichartz GR: Cancer surgery: How may anesthesia influence outcome? J Clin Anesth. 27:262–272. 2015. View Article : Google Scholar : PubMed/NCBI
10	Wu GJ, Chen JT, Tsai HC, Chen TL, Liu SH and Chen RM: Protection of dexmedetomidine against ischemia/reperfusion-induced apoptotic insults to neuronal cells occurs via an intrinsic mitochondria-dependent pathway. J Cell Biochem. 118:2635–2644. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wang SL, Duan L, Xia B, Liu Z, Wang Y and Wang GM: Dexmedetomidine preconditioning plays a neuroprotective role and suppresses TLR4/NF-kB pathways model of cerebral ischemia reperfusion. Biomed Pharmacother. 93:1337–1342. 2017. View Article : Google Scholar : PubMed/NCBI
12	Cui J, Zhao H, Wang C, Sun JJ, Lu K and Ma D: Dexmedetomidine attenuates oxidative stress induced lung alveolar epithelial cell apoptosis in vitro. Oxid Med Cell Longev. 2015:3583962015. View Article : Google Scholar : PubMed/NCBI
13	Cho JS, Shim JK, Soh S, Kim MK and Kwak YL: Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int. 89:693–700. 2016. View Article : Google Scholar : PubMed/NCBI
14	Szpunar MJ, Burke KA, Dawes RP, Brown EB and Madden KS: The antidepressant desipramine and alpha2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Phila). 6:1262–1272. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bruzzone A, Pinero CP, Castillo LF, Sarappa MG, Rojas P, Lanari C and Luthy IA: Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 155:494–504. 2008. View Article : Google Scholar : PubMed/NCBI
16	Castillo LF, Rivero EM, Goffin V and Luthy IA: Alpha2-adrenoceptor agonists trigger prolactin signaling in breast cancer cells. Cell Signal. 34:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
17	Deng F, Ouyang M, Wang X, Yao X, Chen Y, Tao T, Sun X, Xu L, Tang J and Zhao L: Differential role of intravenous anesthetics in colorectal cancer progression: Implications for clinical application. Oncotarget. 7:77087–77095. 2016. View Article : Google Scholar : PubMed/NCBI
18	Virtanen R: Pharmacological profiles of medetomidine and its antagonists, atipamezole. Acta Vet Scand Suppl. 85:29–37. 1989.PubMed/NCBI
19	Liang H, Yang CX, Zhang B, Wang HB, Liu HZ, Lai XH, Liao MJ and Zhang T: Sevoflurane suppresses hypoxia-induced growth and metastasis of lung cancer cells via inhibiting hypoxia-inducible factor-1α. J Anesth. 29:821–830. 2015. View Article : Google Scholar : PubMed/NCBI
20	Peng JK, Shen SQ, Wang J, Jiang HW and Wang YQ: Etaypoxia-inducible factor 1-α promotes colon cell proliferation and migration by upregulating AMPK-related protein kinase 5 under hypoxic conditions. Oncol Lett. 15:3639–3645. 2018.PubMed/NCBI
21	Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, Cheng D, Chen H, Deng X, Peng C and Shen B: Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 16:1692017. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A and Rathinavelu A: Matrix metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol. 56:100–115. 2019. View Article : Google Scholar : PubMed/NCBI
24	Zhang W, Zhang JQ, Meng FM and Xue FS: Dexmedetomidine protects against lung ischemia-reperfusion injury by the PI3K/Akt/HIF-1α signaling pathway. J Anesth. 30:826–833. 2016. View Article : Google Scholar : PubMed/NCBI
25	Piegeler T and Beck-Schimmer B: Anesthesia and colorectal cancer-The perioperative period as a window of opportunity? Eur J Surg Oncol. 42:1286–1295. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wigmore TJ, Mohammed K and Jhanji S: Long-term survival for patients undergoing volatile versus IV anesthesia for cancer surgery: A retrospective analysis. Anesthesiology. 124:69–79. 2016. View Article : Google Scholar : PubMed/NCBI
27	Xie Z: Cancer prognosis: Can anesthesia play a role? Anesthesiology. 119:501–503. 2013. View Article : Google Scholar : PubMed/NCBI
28	Terry S, Buart S and Chouaib S: Hypoxic stress-induced tumor and immune plasticity, suppression, and impact on tumor heterogeneity. Front Immunol. 8:16252017. View Article : Google Scholar : PubMed/NCBI
29	Athanasoula KCh, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A and Mantzourani M: Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett. 347:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
30	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
31	Rankin EB and Giaccia AJ: Hypoxic control of metastasis. Science. 352:175–180. 2016. View Article : Google Scholar : PubMed/NCBI
32	Li X, Liu X, Xu Y, Liu J, Xie M, Ni W and Chen S: KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung cancer cells via HIF-1α. Int J Oncol. 45:1507–1514. 2014. View Article : Google Scholar : PubMed/NCBI
33	Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, et al: Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer. FEBS J. 281:115–128. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ai P, Shen B, Pan H, Chen K, Zheng J and Liu F: MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α. J Thromb Thrombolysis. 45:264–273. 2018. View Article : Google Scholar : PubMed/NCBI
35	Yang L, Shen L, Li G, Yuan H, Jin X and Wu X: Silencing of hypoxia inducible factor-1α gene attenuated angiotensin-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice. Atherosclerosis. 252:40–49. 2016. View Article : Google Scholar : PubMed/NCBI
36	Gu J, Sun P, Zhao H, Watts HR, Sanders RD, Terrando N, Xia P, Maze M and Ma D: Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care. 15:R1532011. View Article : Google Scholar : PubMed/NCBI
37	Zhang XY, Liu ZM, Wen SH, Li YS, Li Y, Yao X, Huang WQ and Liu KX: Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats. Anesthesiology. 116:1035–1046. 2012. View Article : Google Scholar : PubMed/NCBI